Literature DB >> 10411234

Relationships between IGF-I and age, gender, body mass, fat distribution, metabolic and hormonal variables in obese patients.

M Maccario1, J Ramunni, S E Oleandri, M Procopio, S Grottoli, R Rossetto, P Savio, G Aimaretti, F Camanni, E Ghigo.   

Abstract

OBJECTIVE: To compare insulin-like growth factor-I (IGF-I) concentrations in obese and normal subjects, and evaluate the possible relationships between IGF-I concentrations and demographic, anthropometric, metabolic and hormonal variables in obese patients. SUBJECTS AND METHODS: 286 obese outpatients (OB, 234 female and 52 male; age 18-71 y, body mass index (BMI) > 27 kg/m2) were recruited. MEASUREMENTS: BMI, waist-to-hip ratio (WHR), serum basal and oral glucose tolerance test (OGTT)-stimulated glucose and insulin concentrations, IGF-I, basal growth hormone (GH), prolactin (PRL), androgens, thyrotropin (TSH), free triiodothyronine (fT3), free thyroxine (fT4), free fatty acids (FFA), triglycerides, total and high density lipoprotein (HDL)-cholesterol, 24h-urinary cortisol levels and blood pressure (BP) values were measured. IGF-I concentrations were also evaluated in a large population of 326 age-matched controls (controls, 228 women, 98 men; age 20-86 y, BMI < 25 kg/m2).
RESULTS: IGF-I concentrations were lower in OB than in controls (age-adjusted mean: 21.6 vs 23.6 nmol/L, P < 0.03). However, individual IGF-I concentrations in OB were within the age-adjusted normal range. In both groups, IGF-I concentrations were gender-independent, and showed a simple negative correlation with age (r = -0.47). In OB, univariate analysis also shows that IGF-I concentrations were negatively correlated with BMI (r = -0.33), but not WHR, with both basal (r = -0.16) and OGTT-stimulated glucose levels (r = -0.17), as well as FFA levels (r = -0.19), and with both diastolic and systolic BP (both r = -0.17). In OB women, IGF-I concentrations positively correlated with PRL (r = 0.31), testosterone (r = 0.30), androstenedione (r = 0.30), and dehydroepiandrosterone-sulfate (DHEAS) concentrations (r = 0.41). No correlation was found with other variables. The multiple regression analysis showed that IGF-I concentrations were inversely and independently related to age and BMI only.
CONCLUSIONS: In obesity, IGF-I concentrations are slightly reduced, but generally within the age-adjusted normal range. IGF-I concentrations in obesity show independent and negative relationships with age and BMI, but are not associated with fat distribution, insulin secretion, glucose tolerance, BP or risk indices for cardiovascular disease (CVD).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411234     DOI: 10.1038/sj.ijo.0800889

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  20 in total

1.  Determinants of IGF1 and GH across the weight spectrum: from anorexia nervosa to obesity.

Authors:  D J Brick; A V Gerweck; E Meenaghan; E A Lawson; M Misra; P Fazeli; W Johnson; A Klibanski; K K Miller
Journal:  Eur J Endocrinol       Date:  2010-05-25       Impact factor: 6.664

Review 2.  Hormonal regulation of longevity in mammals.

Authors:  Holly M Brown-Borg
Journal:  Ageing Res Rev       Date:  2007-02-20       Impact factor: 10.895

3.  Relationship of obesity and physical activity with C-peptide, leptin, and insulin-like growth factors in breast cancer survivors.

Authors:  Melinda L Irwin; Anne McTiernan; Leslie Bernstein; Frank D Gilliland; Richard Baumgartner; Kathy Baumgartner; Rachel Ballard-Barbash
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-12       Impact factor: 4.254

4.  Prevalence and characteristics of metabolic syndrome in primary hyperparathyroidism.

Authors:  F Tassone; L Gianotti; C Baffoni; F Cesario; G Magro; M Pellegrino; I Emmolo; M Maccario; G Borretta
Journal:  J Endocrinol Invest       Date:  2011-12-21       Impact factor: 4.256

5.  Epidemiologic survey: reference ranges of serum insulin-like growth factor 1 levels in Caucasian adult population with immunoradiometric assay.

Authors:  Fahri Bayram; Vedia Tonyukuk Gedik; Özgür Demir; Ahmet Kaya; Kürşat Gündoğan; Rıfat Emral; Ahmet Öztürk; Ali Rıza Uysal; Demet Çorapçıoğlu
Journal:  Endocrine       Date:  2011-05-03       Impact factor: 3.633

6.  IGF-1 Levels are Inversely Associated With Metabolic Syndrome in Obstructive Sleep Apnea.

Authors:  Suelem Izumi; Fernando F Ribeiro-Filho; Gláucia Carneiro; Sônia M Togeiro; Sérgio Tufik; Maria T Zanella
Journal:  J Clin Sleep Med       Date:  2016-04-15       Impact factor: 4.062

7.  A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance.

Authors:  Christopher B Newgard; Jie An; James R Bain; Michael J Muehlbauer; Robert D Stevens; Lillian F Lien; Andrea M Haqq; Svati H Shah; Michelle Arlotto; Cris A Slentz; James Rochon; Dianne Gallup; Olga Ilkayeva; Brett R Wenner; William S Yancy; Howard Eisenson; Gerald Musante; Richard S Surwit; David S Millington; Mark D Butler; Laura P Svetkey
Journal:  Cell Metab       Date:  2009-04       Impact factor: 27.287

8.  Insulin-like growth factor-I is inversely related to adiposity in overweight Latino children.

Authors:  Claudia M Toledo-Corral; Christian K Roberts; Gabriel Q Shaibi; Christianne J Lane; Paul B Higgins; Jaimie N Davis; Marc J Weigensberg; Michael I Goran
Journal:  J Pediatr Endocrinol Metab       Date:  2008-09       Impact factor: 1.634

9.  Relationship between growth hormone/insulin-like growth factor-1 axis integrity and voluntary weight loss after gastric banding surgery for severe obesity.

Authors:  Silvia Savastano; Luigi Angrisani; Carolina Di Somma; Francesca Rota; Maria Cristina Savanelli; Teresa Cascella; Francesco Orio; Gaetano Lombardi; Annamaria Colao
Journal:  Obes Surg       Date:  2009-07-28       Impact factor: 4.129

10.  Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women.

Authors:  Andrea L Utz; Ami Yamamoto; Linda Hemphill; Karen K Miller
Journal:  J Clin Endocrinol Metab       Date:  2008-04-29       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.